Pharmaceuticals

Postherpetic Neuralgia (PHN) Market Forecast 2026–2035: Data Trends and Industry Insights

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the postherpetic neuralgia (phn) market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Postherpetic Neuralgia (PHN) Market between 2026 and 2030?

The postherpetic neuralgia (phn) market size has shown significant expansion in recent years. This market is anticipated to increase from $0.77 billion in 2025 to $0.82 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. The historical growth can be attributed to several factors, including the rising incidence of herpes zoster infections, the limited array of treatment options for neuropathic pain, the continued reliance on opioid-based pain management, an expanding elderly population, and the progressive expansion of hospital pain management services.

The postherpetic neuralgia (phn) market is poised for robust expansion over the next few years. It is expected to grow to $1.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period can be attributed to factors such as the development of targeted neuropathic pain therapies, increasing adoption of biologic and branded drugs, the proliferation of online pharmacy distribution channels, a heightened focus on patient-centric pain management, and the expansion of outpatient and ambulatory care facilities. Notable trends for the forecast period include a rising prevalence of shingles in the aging population, increasing adoption of non-opioid pain management therapies, the growing use of transdermal and topical pain relief solutions, a higher demand for long-term chronic pain management, and improved awareness leading to early diagnosis of phn.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Postherpetic Neuralgia (PHN) Market?

The market for postherpetic neuralgia (PHN) is projected to grow, driven by the rising occurrence of chronic pain conditions. Chronic pain is defined as ongoing or intermittent discomfort that persists for over 3 months, frequently extending past the typical recovery period from an illness or injury, thereby impacting an individual’s daily activities and overall well-being. The higher incidence of chronic pain conditions can be attributed to an aging demographic, given that elderly individuals are more susceptible to degenerative ailments such as arthritis and neuropathy, which cause enduring pain. Postherpetic neuralgia serves as a valuable subject for chronic pain research, offering a distinct model for investigating nerve-related pain mechanisms and assessing long-term therapeutic approaches. As an illustration, a report from the UK government’s Office for Health Improvement and Disparities in January 2024 indicated that approximately 18.4% of individuals aged 16 and over reported a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Consequently, the expanding occurrence of chronic pain conditions is fueling the growth within the postherpetic neuralgia (PHN) market.

How Is The Postherpetic Neuralgia (PHN) Market Organized Into Various Segments?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

Which Trends Are Influencing The Performance And Direction Of The Postherpetic Neuralgia (PHN) Market?

Leading companies in the postherpetic neuralgia (PHN) market are concentrating on securing regulatory approvals to expand their product portfolios, gain a competitive edge, and fulfill the substantial unmet clinical requirement for more effective and tolerable treatments. Regulatory approvals are the official permissions granted by government health authorities, enabling a drug or treatment to be legally commercialized and used for a specific medical condition. For instance, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, achieved final United States Food and Drug Administration approval to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, indicated for the management of postherpetic neuralgia (PHN). These gabapentin tablets are designed for treating PHN, a form of neuropathic pain caused by nerve damage from the reactivation of the varicella-zoster virus. For PHN, the customary dosage commences at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with titration up to a maximum of 1800 mg per day (600 mg three times daily) as necessary for pain alleviation.

Who Are The Core Companies Influencing Trends In The Postherpetic Neuralgia (PHN) Market?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Regions Are Projected To Dominate The Postherpetic Neuralgia (PHN) Market In The Coming Years?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Postherpetic Neuralgia (PHN) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24664&type=smp

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795